Benzodiazepine Usage, Healthcare Resource Utilization, and Costs Among Older Adults Treated with Common Insomnia Medications: A Retrospective Cohort Study.

IF 2.1 Q3 HEALTH CARE SCIENCES & SERVICES
Emerson M Wickwire, Timothy R Juday, Deval Gor, Diana T Amari, Feride H Frech
{"title":"Benzodiazepine Usage, Healthcare Resource Utilization, and Costs Among Older Adults Treated with Common Insomnia Medications: A Retrospective Cohort Study.","authors":"Emerson M Wickwire,&nbsp;Timothy R Juday,&nbsp;Deval Gor,&nbsp;Diana T Amari,&nbsp;Feride H Frech","doi":"10.2147/CEOR.S406137","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Benzodiazepines are commonly prescribed for insomnia management but are often associated with negative safety outcomes such as falls and abuse, particularly among older adults.</p><p><strong>Objective: </strong>The purpose of this real-world study was to compare the impact of benzodiazepines, low-dose trazodone, and zolpidem immediate release (IR) on healthcare resource utilization (HCRU), and costs among older adults (age ≥ 65 years) with insomnia in the US.</p><p><strong>Methods: </strong>Using the IBM MarketScan Medicare Supplemental Database, older adults with >1 physician-assigned diagnosis of insomnia and treated with benzodiazepines were matched 1:1 on age, sex, and index-date to individuals treated with trazodone, and separately matched 1:1 on age and sex, to individuals treated with zolpidem immediate release (IR). Between-groups differences were analyzed using general linear models (GLMs) that controlled for multiple confounders.</p><p><strong>Results: </strong>Significant between-groups differences in HCRU and costs were observed such that relative to zolpidem IR and separately relative to low-dose trazodone, benzodiazepines were consistently associated with worsened outcomes.</p><p><strong>Conclusion: </strong>These findings build upon and extend prior knowledge on the negative impact of benzodiazepines and suggest directions for future research.</p>","PeriodicalId":47313,"journal":{"name":"ClinicoEconomics and Outcomes Research","volume":null,"pages":null},"PeriodicalIF":2.1000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f6/28/ceor-15-413.PMC10243345.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ClinicoEconomics and Outcomes Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/CEOR.S406137","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Benzodiazepines are commonly prescribed for insomnia management but are often associated with negative safety outcomes such as falls and abuse, particularly among older adults.

Objective: The purpose of this real-world study was to compare the impact of benzodiazepines, low-dose trazodone, and zolpidem immediate release (IR) on healthcare resource utilization (HCRU), and costs among older adults (age ≥ 65 years) with insomnia in the US.

Methods: Using the IBM MarketScan Medicare Supplemental Database, older adults with >1 physician-assigned diagnosis of insomnia and treated with benzodiazepines were matched 1:1 on age, sex, and index-date to individuals treated with trazodone, and separately matched 1:1 on age and sex, to individuals treated with zolpidem immediate release (IR). Between-groups differences were analyzed using general linear models (GLMs) that controlled for multiple confounders.

Results: Significant between-groups differences in HCRU and costs were observed such that relative to zolpidem IR and separately relative to low-dose trazodone, benzodiazepines were consistently associated with worsened outcomes.

Conclusion: These findings build upon and extend prior knowledge on the negative impact of benzodiazepines and suggest directions for future research.

Abstract Image

Abstract Image

在接受常见失眠药物治疗的老年人中,苯二氮卓类药物的使用、医疗资源的利用和成本:一项回顾性队列研究
背景:苯二氮卓类药物通常用于失眠治疗,但通常与负面的安全性结果相关,如跌倒和滥用,特别是在老年人中。目的:本现实世界研究的目的是比较苯二氮卓类药物、低剂量曲唑酮和唑吡坦立即释放(IR)对美国老年人(≥65岁)失眠患者的医疗资源利用(HCRU)和成本的影响。方法:使用IBM MarketScan医疗保险补充数据库,将有>1个医生指定诊断为失眠并接受苯二氮卓类药物治疗的老年人在年龄、性别和指标日期上与曲唑酮组进行1:1匹配,并将年龄和性别与唑吡坦立即释放(IR)组进行1:1匹配。使用控制多个混杂因素的一般线性模型(GLMs)分析组间差异。结果:观察到组间HCRU和成本的显著差异,因此相对于唑吡坦IR和单独相对于低剂量曲唑酮,苯二氮卓类药物始终与恶化的结果相关。结论:这些发现建立并扩展了对苯二氮卓类药物负面影响的现有认识,并为今后的研究指明了方向。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
ClinicoEconomics and Outcomes Research
ClinicoEconomics and Outcomes Research HEALTH CARE SCIENCES & SERVICES-
CiteScore
3.70
自引率
0.00%
发文量
83
审稿时长
16 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信